An Audit of Staphylococcus aureus Bacteraemia Treatment in a UK District General Hospital

Yıl 2017, Cilt: 07 Sayı: 04, 188 - 193, 01.12.2017

Christine Scarsbrook Nadeem Sajjad Raja Michael Hardman Kath Hughes

https://doi.org/10.5799/jmid.369266

Öz

Objective: Recent guidelines from Healthcare Improvement Scotland
recommend that uncomplicated Staphylococcus aureus bacteraemia (SAB) be treated
with effective antibiotics for at least 14 days.  This audit aimed to see whether Medway
Hospital, UK, was following these guidelines, and whether a simple intervention
could improve compliance and therefore treatment.

Method:
All patients with SAB between April 2013 and September 2014 were identified and
their clinical notes, laboratory findings and drug charts were reviewed.
Starting in January 2014 all SAB were reported on the online pathology results
system with the following advice; ‘Staphylococcus aureus bacteraemia warrants a
minimum of 14 days treatment. Treatment may be longer in cases of deep seated
infection.’ Outcome measures included 14 days antimicrobial treatment
readmission rate with SAB, 3 month mortality post treatment and whether
echocardiography was performed.

Results:
The demographics of all patients (35 pre and 39 post intervention) were
comparable between groups (average age 63 vs 56, 54.3% vs 69.2% male) although
the sources of bacteraemia differed slightly. More patients had indwelling
lines in 2013 and there were a higher proportion of IV drug users in 2014; all
other risk factors were similar between groups. More patients received
appropriate antibiotics post intervention (74% vs 49%). Three month mortality
with community acquired SAB increased but mortality with hospital acquired SAB decreased
post intervention. Echocardiography uptake improved, and readmission rates with
SAB decreased.

Conclusion: The introduction of guidance with blood culture
results has demonstrated better compliance with a 14 day minimum treatment
length for SAB.  Although sample size
limits obtaining a statistically significant difference in readmission and
mortality rates, this intervention still has the potential to improve treatment
of SAB in aiding clinicians to follow guidelines. J Microbiol Infect Dis 2017; 7(4):188-193

Anahtar Kelimeler

HIV, HCV, Genotype, Co-infection, Viral load

Kaynakça

• 1) Thwaites GE, Edgeworth JD, Gkrania-Klotsas E, et al. UK Clinical Infection Research Group. Clinical Management of Staphylococcus aureus Bacteraemias. Lancet Infect Dis 2011; 11: 208-22. 2) Van Hal SJ, Jenson S, Vaska V, et al. Predictors of Mortality in Staphlococcus aureus Bacteraemia. Clin Microbiol Rev 2012; 25: 362-386. 3) Wyllie D, Crooke D, Peto T. Mortality after Staphylococcus aureus bacteraemia in two hospitals in Oxfordshire, 1997-2003: cohort study. BMJ 2006; 333: 281. 4) Health Protection England: Health Protection Report. Voluntary surveillance of Staphylococcus aureus bacteraemia in England, Wales and Northern Ireland: 2007-2014 [online] (2015). Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/455607/hpr2915_saureus.pdf [Accessed 30.04.2016]. 5) Holland TL, Arnold C, Fowler VG Jr. Clinical Management of Staphylococcus Bacteremia: A Review. JAMA 2014; 312: 1330-1341. 6) Bai AD, Showler A, Burry L, et al. Impact of Infectious Disease Consultation on Quality of Care, Mortality, and Length of Stay in Staphylococcus aureus Bacteremia: Results From a Large Multicenter Cohort Study. Clin Infect Dis 2015; 60: 1451-1461. 7) Lahey T, Shah R, Gittzus J, Schwartzman J, Kirkland K. Infectious diseases consultation lowers mortality from Staphylococcus aureus bacteremia. Medicine (Baltimore); 88: 263-267. 8) Fowler VG Jr, Sanders LL, Sexton DJ, et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis 1998; 27: 478. 9) Healthcare Improvement Scotland. Guidance on management of proven or suspected Staphylococcus aureus bacteraemia in adults (2015). [online] Available at: https://www.scottishmedicines.org.uk/files/sapg1/SAB_algorithm.pdf [Accessed 04.05.2016]. 10) Gould FK, Brindle R, Chadwick PR, et al. MRSA Working Party of the British Society for Antimicrobial Chemotherapy. Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdomp. J Antimicrob Chemother 2009; 63: 849-861. 11) Liu C, Bayer A, Cosgrove SE, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children. Clin Infect Dis 2011; 52: 18-55. 12) Jensen AG, Wachmann CH, Espersen F, Scheibel J, Skinhøj P, Frimodt-Møller N. Treatment and outcome of Staphylococcus aureus bacteraemia: a prospective study of 278 cases. Arch Intern Med 2002; 162: 25-32. 13) Chong YP, Moon SM, Bang KM, et al. Treatment duration for uncomplicated Staphylococcus aureus bacteraemia to prevent relapse: analysis of a prospective observational cohort study. Antimicrob Agent Chemother 2013; 57:1150-1156. 14) Thwaites GE; United Kingdom Clinical Infection Research Group (UKCIRG). The management of Staphylococcus aureus bacteremia in the United Kingdom and Vietnam: a multi-centre evaluation. PLoS One 2010; 13; 5 (12):e14170. 15) EUCAST disk diffusion method. The British Society for Antimicrobial Chemotherapy, (2016). available at: http://bsac.org.uk/eucastbsac-disc-diffusion-method/ [Accessed 02.01.2017]. 16) Ringberg H, Thoren A, Lilja B. Metastatic complications of Staphlococcus aureus septicaemia. To seek is to find. Infection 2000; 28(3): 132-36. 17) López-Cortés LE, Del Toro MD, Gálvez-Acebal J, et al. REIPI/SAB group. Impact of an evidence-based bundle intervention in the quality-of-care management and outcome of Staphylococcus aureus bacteremia. Clin Infect Dis 2013; 57(9):1225-33. 18) Turnidge JD, Kotsanas D, Munckhof W, et al. Australia New Zealand Cooperative on Outcomes in Staphylococcal Sepsis. Staphylococcus aureus bacteraemia: a major cause of mortality in Australia and New Zealand. Med J Aust 2009 Oct 5; 191(7):368-373. 19) Tong SY, Bishop EJ, Lilliebridge RA, et al. 2009. Community-associated strains of methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus in indigenous northern Australia: epidemiology and outcomes. J Infect Dis 2009; 199: 1461–1470.